Regulus Therapeutics
RGLS
#7021
Rank
โ‚ฌ0.47 B
Marketcap
6,88ย โ‚ฌ
Share price
0.00%
Change (1 day)
364.10%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚ฌ44.02 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚ฌ38.98 Million a decrease over its 2023 earnings that were of -โ‚ฌ24.83 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚ฌ44.02 Million12.94%
2024 -โ‚ฌ38.98 Million56.97%
2023 -โ‚ฌ24.83 Million6.51%
2022 -โ‚ฌ23.32 Million2.53%
2021 -โ‚ฌ22.74 Million93.59%
2020 -โ‚ฌ11.75 Million-15.41%
2019 -โ‚ฌ13.89 Million-64.46%
2018 -โ‚ฌ39.07 Million-33.26%
2017 -โ‚ฌ58.53 Million-13.98%
2016 -โ‚ฌ68.05 Million44.77%
2015 -โ‚ฌ47.01 Million-1.63%
2014 -โ‚ฌ47.79 Million203.6%
2013 -โ‚ฌ15.74 Million8.65%
2012 -โ‚ฌ14.49 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚ฌ7.67 B-19,287.12%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ1.60 B-4,114.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ6.77 B-17,036.90%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ11.04 B-27,699.15%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ7.86 B-19,756.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚ฌ91.98 Million 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚ฌ99.26 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ0.10 B-374.76%๐Ÿ‡บ๐Ÿ‡ธ USA